Last reviewed · How we verify
Bigitalin (gitoxin)
Bigitalin (generic name: gitoxin) is a drug. It is currently in unknown development.
Gitoxin works by interacting with cardiac ion channels to regulate heart rhythm.
Gitoxin, also known as Bigitalin, is a small molecule medication with unknown drug class and target. It is not FDA approved for any indications. The commercial status of gitoxin is unclear, and it is not known whether it is patented or available as a generic medication. Key safety considerations are not well-documented. Further research is needed to understand the pharmacology and clinical use of gitoxin.
At a glance
| Generic name | gitoxin |
|---|---|
| Therapeutic area | Cardiovascular |
| Phase | unknown |
Mechanism of action
Imagine your heart is like a orchestra, and gitoxin is like a conductor that helps the different parts of the heart work together in sync. It does this by affecting the electrical signals that control the heartbeat, helping to prevent irregular rhythms. This can be especially important for people with conditions like atrial fibrillation.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bigitalin CI brief — competitive landscape report
- Bigitalin updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Bigitalin
What is Bigitalin?
How does Bigitalin work?
What is the generic name of Bigitalin?
What development phase is Bigitalin in?
Related
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Cardiovascular
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing